NMD-VCell Neuromuscular Virtual Cell Research Platform Neuromuscular Virtual Cell Platform · Evidence → perturbation → experiment → outcome NMD = neuromuscular disorders
For Reviewers Evidence Status Claims

Evidence Release 2026.08DMD context observedDMD candidate-conditioned prediction locked

View scientific status
Evidence freeze: 3 August 2026 P59 hold · scorer failure retained · no target score NAR working package · 6 main + 31 supplementary figures Resource: v1.2.0-measured-dmd-evidence Schema: 1.1 Open platform state → Open Trust Center → Open evidence dashboard → Open claim registry → Open release status →

NMD disease evidence atlas · multidisease-evidence-v0.2.0

Four diseases, one evidence contract, no pooled biological score.

DMD, FSHD, DM1 and SMA now share the same route and API shape while retaining different disease anchors, models, unit structures and claim ceilings.

Compare diseasesSee module scopeOpen API manifestOpenAPI

Module meaning contract

Diseases · what this module can change

See all eight modules →
Question answeredWhat has been measured, induced, corrected, perturbed or remains missing in each disease?
Scope & evidence unitDMD, FSHD, DM1 and SMA disease-specific evidence modules; each retains its own biological model, statistical unit and claim ceiling.Dataset-specific biological unit—donor, biopsy, clone, well or donor-derived line; individual cells are not treated as independent biological replicates by default.
ProducesTyped disease summary, dataset registry, role-typed candidate objects, strict evidence states and a disease-specific next experiment.
Cannot establishNo pooled cross-disease score, disease winner, treatment ranking, calibrated patient simulation or clinical recommendation.

Next handoffChoose a disease route; use the DMD interactive workflow where supported or follow the disease-specific next experiment. Continue →

v0.1 preservedArchived 3-module APIAll v01 figures/downloads remain available; v0.2 adds the DMD adapter and strict schema.
Measured DMD core · prospective validation

DMD

Dystrophin loss

Measured DMD induction and locus correction are connected to a governed 21-candidate prospective test queue.

Deep measured context · candidate outcome pendingOpen unified disease route →Patient state · induced timing · directional scRNA

FSHD

DUX4

Sparse patient-state activation is linked to a causal DUX4 time course and an analysis-plan-frozen membrane-injury extension.

Measured + induced · line-blocked directional extensionOpen unified disease route →Patient evidence · isogenic correction

DM1

DMPK CTG repeat

Repeat excision and patient splicing are linked without collapsing PSI into global expression rescue.

Measured splicing · isogenic correctionOpen unified disease route →Neural response · residual muscle · directional scRNA

SMA

SMN1 / SMN2

Human neural response evidence is separated from residual treated-muscle signals and a registered cell-resolution extension.

Measured neural response · line-aggregated extensionOpen unified disease route →

Evidence to action

Each disease hands off to a different decisive object.

Disease-specific · not ranked
DiseaseWhat is established nowNext decisive objectCorrect handoff
DMDMeasured induction/correction plus patient-muscle pathways; 21 candidates remain prospective.Matched DMD/control myogenic perturbation with a frozen endpoint.Open DMD question gate →
FSHDPatient state, causal DUX4 timing and line-aware membrane-injury localization.Line-balanced perturbation of membrane-repair/ferroptotic hypotheses with donor-level inference.Open FSHD evidence →
DM1Repeat correction converges with patient evidence on 36 splicing genes, not global expression rescue.Orthogonal splicing and function validation with clone/biopsy units preserved.Open DM1 evidence →
SMANeural intervention response and residual treated-muscle signals remain context-separated.Line-balanced, state-specific functional response test without inferring motor outcome.Open SMA evidence →

DMD has interactive Questions, Gene compare and draft Study Cards. FSHD, DM1 and SMA currently hand off to disease-specific evidence and next-experiment recommendations; they do not inherit the DMD predictor or prospective registry.

Selected cross-version architecture

The richer curated Figure 1 replaces the reduced three-module diagram.

Download SVG
Four disease modules with strict evidence states, unit structures, permitted uses and claim ceilings.

Candidate logic

Anchors, markers, endpoints and candidates are role-typed.

Role-typed candidate establishment and disease-specific next experiments.
Available
  • Four unified disease routes
  • Strict state plus qualifiers
  • Stable candidate and dataset IDs
  • Source-level null and missing evidence
Unavailable
  • Cross-disease winner score
  • Calibrated patient simulation
  • Treatment ranking
  • Clinical recommendation